Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.55% to 5,770.20 and the Dow Jones Industrial Average DJIA rising 0.52% to 42,801.72.

Teladoc (TDOC) shares are climbing on Thursday after the healthcare company announced its deal with Eli Lilly's (LLY) direct-to-consumer pharmacy partner Lilly Direct. The deal is set to streamline consumer access to the weight loss drug Zepbound.

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from a late-stage study on next-generation obesity drug, CagriSema. Top-line data from the phase III REDEFINE 2 study on Novo Nordisk’s CagriSema showed that treatment with the drug led to a weight loss of 15.